Key Drivers
- High margins
- Strong cash flow
- Healthy balance sheet
AIAI Summary
CLBT has shifted from a premium growth story to a credibility-and-execution test after the Q2 miss, ARR guide cut, delayed cloud deals, and CEO transition, so the stock likely stays capped until management proves it can reliably convert demand into recurring revenue and reclaim the 12.4-14.2 resistance zone, even though the strong balance sheet and software-like margins limit downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Strong cash flow
- •Healthy balance sheet
CLBT shows strong software-like margins, solid cash generation, and a healthy balance sheet, but its premium valuation and recent quarterly margin compression limit upside.
Price Behavior
Key Price Behavior Insights:
- •Support breakdown
- •Oversold bounce
- •Resistance overhead
CLBT has rolled from a choppy range into a clear downtrend over the last month, with a 30% drop after the 8/13 breakdown from the $14.0-$14.2 support zone; the bounce to $11.14 looks oversold but price remains below reclaimed resistance, so the chart stays fragile until $12.4-$14.2 is regained.
Sharp collapse from the mid-$15s to $10.80 on 2026-08-13 triggered a major breakdown
Sentiment & News
Key News Insights:
- •Missed estimates
- •Outlook cut
- •Probe risk
Cellebrite missed Q2 estimates, cut its 2026 ARR/revenue outlook, and saw its stock plunge over 30% as CEO transition news and securities-law investigations followed.
The miss and lowered guidance point to near-term downside pressure on Cellebrite shares amid heightened legal and execution uncertainty
Similar Companies in Technology
Other companies in the same sector with AI ratings